Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos Therapeutics receives Nasdaq delisting notice for failing minimum equity requirement again

Vivos Therapeutics, Inc.

On May 16, 2024, Nasdaq notified Vivos that stockholders' equity fell below $2.5M as of March 31, 2024.
Company previously regained compliance on May 6, 2024, but new Q1 10-Q filing shows equity < $2.5M.
Company has filed appeal; delisting is stayed pending Hearing Panel decision.
If delisted, material adverse effect on stock price, liquidity, capital raising, and reputation.
No assurance the company can regain or maintain compliance with the minimum equity requirement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

rch 31, 2024) being less than $2.5 million. The Notice also indicated that Nasdaq would commence delisting proceedings against the Company. The Company has the right to, and has already filed for, an appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, to request an additional hearing on this matter before the Hearing Panel. The Company’s appeal has stayed any delisting or suspension action by the Nasdaq staff pending the issuance of the Hearing’s Panel decision. The Company’s common stock will remain listed on Nasdaq, pending th

View on SEC.gov

97 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-020446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.